Clinical trials: CDA
Leukemia
Chemotherapy in Treating Children With Recurrent Acute Myeloid Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00003178
- Testing
- filgrastim, cladribine, idarubicin
- Where
- 235 sites in United States, Australia and 5 more
- Volunteers
- 120 people
- Sponsor
- Children's Oncology Group
Advanced Multiple Sclerosis, Progressive Multiple Sclerosis
ChariotMS - Cladribine to Halt Deterioration in People With Advanced Multiple Sclerosis
MS is a chronic inflammatory and degenerative disease of the central nervous system (CNS) affecting more than 120,000 people in the UK.and 2.5 million people worldwide.
- Trial name
- ChariotMS (NCT04695080)
- Testing
- Cladribine (MAVENCLAD®)
- Where
- 22 sites in United Kingdom
- Volunteers
- 204 people
- Sponsor
- Queen Mary University of London
Pulmonary Disease, Chronic Obstructive, Smoking
Electronic Proactive Outreach for Smokers With COPD
Chronic obstructive pulmonary disease (COPD) is one of the most common respiratory diseases, with 90% of cases directly attributable to smoking. Unfortunately, many patients continue to smoke and have an urgent need to quit.
- Trial name
- NCT04462289
- Testing
- Proactive Outreach
- Where
- United States
- Volunteers
- 124 people
- Sponsor
- VA Office of Research and Development
Multiple Sclerosis
Cladribine Tablets After Treatment With Natalizumab (CLADRINA)
The purpose of this study is to generate hypotheses regarding the safety, efficacy, and immunological impact of cladribine tablets after treatment with natalizumab in patients with relapsing-remitting multiple sclerosis (RRMS)…
- Trial name
- NCT04178005
- Testing
- Cladribine
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- University of Texas Southwestern Medical Center
Multiple Sclerosis
Safety and Efficacy of Cladribine Therapy After Anti CD20 Therapy
Prolonged anti CD20 therapy for the treatment of active multiple sclerosis leading to continuous B cell depletion is associated with hypogammaglobulinemia predisposing to a potentially increased risk of serious infections…
- Trial name
- NCT04640818
- Testing
- Cladribine Oral Tablet, Rituximab, Ocrelizumab
- Where
- Switzerland
- Volunteers
- 45 people
- Sponsor
- Claudio Gobbi
Hematologic Neoplasms, Lymphoproliferative Disorders
Clofarabine in Chronic Lymphocytic Leukemia
This is a dose-escalation study to determine the maximum tolerated dose and toxic effects of clofarabine in patients with chronic lymphocytic leukemia and other acute leukemias.
- Conditions
- Hematologic Neoplasms, Lymphoproliferative Disorders, Leukemia, Leukemia, Lymphocytic, Chronic
- Trial name
- NCT00028418
- Testing
- Clofarabine
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- M.D. Anderson Cancer Center
Chronic Back Pain, Depression
Improving Outcomes for Older Veterans With Chronic Back Pain and Depression
The overarching goal of this study is to develop and evaluate a telephone delivered behavioral change intervention for older Veterans with chronic low back pain (cLBP) and comorbid depression, and to ultimately assess its effect…
- Conditions
- Chronic Back Pain, Depression, Aging
- Trial name
- NCT03896035
- Testing
- Behavioral Intervention Group
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- VA Office of Research and Development
Multiple Sclerosis
Cladribine Tablets Level of Response Predictors in Clinical Practice (CLODINA)
This study aims to describe participants characteristics that can predict the safety and effectiveness of cladribine tablets, as assessed by time-to-discontinuation of treatment with cladribine tablets, and to assess other…
- Trial name
- NCT05797740
- Testing
- Mavenclad
- Where
- 30 sites in Belgium, Czechia and 4 more
- Volunteers
- 366 people
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Prediabetes
INcreasing Veteran EngagemeNT to Prevent Diabetes (INVENT)
This study will evaluate a VA MyHealtheVet Secure Messaging intervention that uses different intervention messaging strategies designed to increase engagement in behaviors to prevent type 2 diabetes.
- Trial name
- INVENT (NCT03403231)
- Testing
- INVENT Secure Messaging Intervention
- Where
- United States
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Acute Myeloid Leukemia
Idarubicin Plus Cytarabine (IA) vs IA Plus Cladribine (IAC) as Induction Regimen to Treat Initially Diagnosed Acute Myeloid Leukemia (AML)
The goal of this clinical trial is to compare the clinical efficacy and safety of IAC regimen and IA regimen as induction chemotherapy for initial diagnosed acute myeloid leukemia (AML) patients.
- Trial name
- NCT02323022
- Testing
- IAC regimen, IA regimen
- Where
- China
- Volunteers
- 618 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Acute Myeloid Leukemia
Conditioning Regimen Containing Melphalan and Cladribine for Refractory / Relapsed AML
This project is a prospective, multicenter, randomized controlled clinical study. The subjects were refractory / relapsed AML patients aged ≤ 60 years diagnosed by bone marrow cell morphology, immunology, genetics and therapeutic…
- Trial name
- NCT06133556
- Testing
- MCBC regimen, Bu/Cy regimen
- Volunteers
- 237 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Relapsed Adult AML, Refractory AML
Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia
This is an open-label phase I study designed to evaluate the safety of venetoclax-navitoclax with cladribine-based salvage therapy.
- Trial name
- NCT06007911
- Testing
- Navitoclax Dose Level -1, Navitoclax Dose Level 0, Navitoclax Dose Level 1
- Where
- United States
- Sponsor
- Medical College of Wisconsin
Leukemia
Bryostatin 1 Plus Cladribine in Treating Patients With Relapsed Chronic Lymphocytic Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003174
- Testing
- bryostatin 1, cladribine
- Where
- 3 sites in United States
- Volunteers
- 80 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Lymphoma
Cladribine in Patients With Mantle Cell Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effects of cladribine in previously treated or untreated patients with…
- Trial name
- NCT00002879
- Testing
- cladribine
- Where
- 21 sites in United States, Canada
- Volunteers
- 51 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Suicide, Firearm Injury
Home Safety Intervention
Access to lethal methods of self-harm such as firearms and medications increases risk for suicide. As such, VA/DoD guidelines for the care of individuals with elevated suicide risk include recommendations that clinicians deliver…
- Conditions
- Suicide, Firearm Injury, Overdose
- Trial name
- HSI (NCT06216327)
- Testing
- household safety intervention
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- VA Office of Research and Development
Acute Lymphoblastic Leukemia
CAV Regimen for R/R Ph- B-ALL
This study aims to investigate the efficacy and safety of cladribine, venetoclax combined with cytarabine and venetoclax (CAV regimen) for relapsed/refractory (R/R) Philadelphia Chromosome-negative (Ph-) B-cell acute…
- Trial name
- NCT05657652
- Testing
- cladribine, cytarabine,venetoclax
- Where
- China
- Volunteers
- 36 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis
Cladribine vs Placebo for Non-active Progressive Multiple Sclerosis (CLASP-MS).
The purpose of the study is to evaluate the efficacy and safety of subcutaneously administered cladribine versus placebo to stop inflammation and treat disease progression of non-active secondary progressive multiple sclerosis.
- Trial name
- CLASP-MS (NCT05961644)
- Testing
- Cladribine Subcutaneous Injection, 0.9% Chloride Injection Sodium
- Where
- Poland
- Volunteers
- 188 people
- Sponsor
- Institute of Psychiatry and Neurology, Warsaw